KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $111.2 million.

  • Recursion Pharmaceuticals' Non-Current Deffered Revenue rose 60776.48% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 60776.48%. This contributed to the annual value of $118.8 million for FY2024, which is 13179.09% up from last year.
  • Recursion Pharmaceuticals' Non-Current Deffered Revenue amounted to $111.2 million in Q3 2025, which was up 60776.48% from $126.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $129.6 million during Q1 2025, with a 5-year trough of $6.7 million in Q4 2021.
  • Its 5-year average for Non-Current Deffered Revenue is $61.2 million, with a median of $51.4 million in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' Non-Current Deffered Revenue skyrocketed by 95386.23% in 2022 and then tumbled by 6942.18% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Non-Current Deffered Revenue stood at $6.7 million in 2021, then surged by 953.86% to $70.3 million in 2022, then decreased by 27.07% to $51.2 million in 2023, then skyrocketed by 131.79% to $118.8 million in 2024, then dropped by 6.37% to $111.2 million in 2025.
  • Its Non-Current Deffered Revenue stands at $111.2 million for Q3 2025, versus $126.2 million for Q2 2025 and $129.6 million for Q1 2025.